Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 5/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 3/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.33 |
| ▸ | CFTR | P13569 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALPG | P10696 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | NPY1R | P25929 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NPY2R | P49146 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL868072 | 0.77 | HSP90AA1 (0.39) | HSP90AA1CA2CA4CA5ATSHR | |
| SCHEMBL10665143 | 0.76 | HSP90AA1 (0.35) | HSP90AA1CA2CA4CA5ATSHR | |
| Bromide SCHEMBL5063713 | 0.74 | HSP90AA1 (0.38) | HSP90AA1CA2CA4CA5ATSHR | |
| SCHEMBL4968872 | 0.71 | CA2 (0.43) | HSP90AA1CA2CA4CA5ATSHR | |
| SCHEMBL6397176 | 0.71 | HSP90AA1 (0.43) | HSP90AA1CA2CA4CA5ATSHR | |
| SCHEMBL3140190 | 0.71 | HSP90AA1 (0.39) | HSP90AA1CA2CA4CA5ATSHR | |
| SCHEMBL688290 | 0.71 | HSP90AA1 (0.43) | HSP90AA1CA2CA4CA5ATSHR | |
| SCHEMBL7633171 | 0.71 | HSP90AA1 (0.39) | HSP90AA1CA2CA4CA5ATSHR | |
| SCHEMBL306807 | 0.71 | TSHR (0.41) | HSP90AA1CA2CA4CA5ATSHR | |
| SCHEMBL16161029 | 0.70 | TSHR (0.38) | HSP90AA1CA2CA4CA5ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022073469-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI) , INC. (CN) | 2022-04-14 | — | — | WO | disclosed |
| US-8106036-B2 | Pharmaceutical compositions-4 | HARBOR BIOSCIENCES, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-7947846-B2 | 15-OXA-steroid compounds | HARBOR BIOSCIENCES, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20100222313-A1 | PHARMACEUTICAL COMPOSITIONS-4 | BIOVIE INC. | 2010-09-02 | — | — | US | disclosed |
| US-20100222425-A1 | COMPOSITIONS AND TREATMENT METHODS-2 | BIOVIE INC. | 2010-09-02 | — | — | US | disclosed |
| US-7723532-B2 | Pharmaceutical compositions 3 | HARBOR BIOSCIENCES, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090215737-A1 | Pharmaceutical Compositions - 2 | BIOVIE INC. | 2009-08-27 | — | — | US | disclosed |
| US-7524835-B2 | Tetrol steroids and esters | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-20080176824-A1 | Pharmaceutical Compositions 3 | BIOVIE INC. | 2008-07-24 | — | — | US | disclosed |
| US-7396827-B2 | Pharmaceutical compositions and treatment methods | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2008-07-08 | — | — | US | disclosed |
| US-20080045490-A1 | Pharmaceutical Compositions | BIOVIE INC. | 2008-02-21 | — | — | US | disclosed |
| US-20070275936-A1 | Formulations and Treatment Methods | BIOVIE INC. | 2007-11-29 | — | — | US | disclosed |
| US-20070275936-A1 | Formulations and Treatment Methods | BIOVIE INC. | 2007-11-29 | — | — | US | disclosed |
| US-20070129282-A1 | Pharmaceutical treatments and compositions | BIOVIE INC. | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045490-A1 | Pharmaceutical Compositions | HSD3B1, HSD17B3, HSD17B1 | HSP90AA1 1772/4885CA2 3762/4885CA4 2901/4885 |
| US-20090215737-A1 | Pharmaceutical Compositions - 2 | HSD3B2, HSD3B1, HSD17B2 | HSP90AA1 2294/4885CA2 2169/4885CA4 3185/4885 |
| US-20070129282-A1 | Pharmaceutical treatments and compositions | HSD3B1, HSD3B2, HSD17B1 | HSP90AA1 1234/4885CA2 3601/4885CA4 2982/4885 |
| US-20100222425-A1 | COMPOSITIONS AND TREATMENT METHODS-2 | MPL, THPO, HSD3B2 | HSP90AA1 916/4885CA2 3704/4885CA4 3360/4885 |
| US-20100222313-A1 | PHARMACEUTICAL COMPOSITIONS-4 | HSD3B1, HSD3B2, HSD17B7 | HSP90AA1 2187/4885CA2 3497/4885CA4 677/4885 |
| US-20080176824-A1 | Pharmaceutical Compositions 3 | HSD3B1, HSD17B3, HSD3B2 | HSP90AA1 1663/4885CA2 3823/4885CA4 3497/4885 |
| US-20070275936-A1 | Formulations and Treatment Methods | HSD3B1, HSD17B1, HSD17B3 | HSP90AA1 1274/4885CA2 3848/4885CA4 2989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.